文献速递临床试验与 GCP

凝血酶原复合物浓缩物与新鲜冰冻血浆治疗成人心脏手术后出血的比较(PROPHESY-2试验):英格兰和威尔士的III期随机对照试验

PROthrombin complex concentrate versus fresh frozen Plasma for bleeding in adults undergoing HEart SurgerY (PROPHESY-2 trial): a phase III, randomised control trial in England and Wales.
PubMed 文献 · Trials · 2026-01-17

PROPHESY-2是一项在英格兰和威尔士最多20家医院开展的III期、实用性、多中心、平行组、优效性、非盲、开放标签、两阶段组序贯随机对照试验,嵌入内部预试验。拟纳入496例心脏手术后24小时内发生严重出血的成人,按1:1随机接受凝血酶原复合物浓缩物(PCC)或新鲜冰冻血浆(FFP),主要终点为90天死亡或新发呼吸衰竭、心肌损伤、肾衰竭、肝损伤、肠损伤、局灶性神经功能缺损或感染复合终点。首例患者入组日期为2025年2月11日。

要点

  • PCC剂量为体重≤70 kg者1500 IU、>70 kg者2000 IU,最多2剂;FFP为≤70 kg者4单位、>70 kg者5单位,无最大剂量限制。
  • 主要终点为90天死亡或新发呼吸衰竭、心肌损伤、肾衰竭、肝损伤、肠损伤、局灶性神经功能缺损或感染的复合终点。
  • 样本量496例,在5%显著性水平下以90%把握度检测两组间90天相对危险度0.7。

核心结论

  • 该试验旨在提供PCC与FFP在心脏手术后出血患者中临床和成本效果的证据,其结果将为心脏手术后出血的管理提供高质量证据。

研究设计与样本

  • III期实用性、多中心、平行组、优效性、非盲、开放标签、两阶段组序贯随机对照试验,嵌入内部预试验,由英格兰和威尔士最多20家医院的研究团队招募参与者。
  • 已提供知情同意且心脏手术后24小时内(择期和紧急手术)发生出血的成人随机接受PCC或FFP,按1:1比例分配,采用最小化法并以研究中心分层。
  • 最小化因素为年龄(≥70岁和<70岁)和计划手术类型(仅瓣膜、大主动脉手术、冠状动脉旁路移植+瓣膜、复杂/联合手术)。
  • 样本量496例,在5%显著性水平下以90%把握度检测两组间90天相对危险度0.7。
  • 首例患者入组日期为2025年2月11日;试验注册号ISRCTN 92114384,注册日期2024年4月16日。

关键数值与推荐

  • PCC剂量:体重≤70 kg者1500 IU,>70 kg者2000 IU,最多2剂。
  • FFP剂量:体重≤70 kg者4单位,>70 kg者5单位,无最大剂量限制。
  • 主要终点为90天死亡或新发呼吸衰竭、心肌损伤、肾衰竭、肝损伤、肠损伤、局灶性神经功能缺损或感染的复合终点。
  • 次要终点比较安全性(输血相关反应、血栓形成)、生活质量、医疗费用和成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fresh frozen plasma (FFP) is the standard treatment for severe bleeding following cardiac surgery. Despite increasing use of prothrombin complex concentrate (PCC) for coagulopathic bleeding in preference to FFP in the UK, the evidence comparing FFP versus PCC in this setting is lacking. HYPOTHESIS: In adults who develop severe bleeding, PCC is superior to FFP in reducing a composite of mortality, organ failure, or infection up to 90 days following cardiac surgery, and is more cost-effective. METHODS: Phase III pragmatic, multicentre, parallel group, superiority, non-blinded, open-label, two-stage group sequential randomised controlled trial with internal pilot embedded. Participants will be recruited by the research team at up to 20 hospitals in England and Wales. Those who have provided informed consent and who develop bleeding within 24 h of cardiac surgery (elective and urgent procedures) will be randomised to PCC (1500 IU if ≤70 kg or 2000 IU if >70 kg; a maximum of 2 doses) or FFP (4 units if ≤70 kg and 5 units if >70 kg; no maximum dose). Randomisation will be stratified by site and will allocate participants using minimisation, with a 1:1 ratio to receive PCC or FFP. Age (≥70 and <70 years) and planned type of surgery (valve only, major aortic surgery, coronary artery bypass graft + valve, and complex/combined procedure) will be the minimisation factors. The primary outcome is a composite of mortality or new onset of respiratory failure, myocardial injury, renal failure, liver injury, intestinal injury, focal neurological deficit, or infection at 90 days. Secondary outcomes will compare safety (transfusion-related reactions, thrombosis), quality of life, healthcare costs, and cost-effectiveness. A sample size of 496 participants will have a 90% power (with a 5% significance level) to detect a relative risk of 0.7 between the two groups at 90 days. The date of the 1st patient enrolled was 11th February 2025. DISCUSSION: This trial will provide evidence on the clinical/cost-effectiveness of PCC versus FFP in cardiac surgery patients who bleed post-surgery. Its outcome will provide high-quality evidence to inform the management of bleeding following cardiac surgery. TRIAL REGISTRATION: ISRCTN 92114384. Registered on 16/04/2024. ISRCTN-ISRCTN92114384: PROthrombin complex concentrate versus fresh frozen Plasma for bleeding in adults undergoing HEart SurgerY (PROPHESY-2 trial).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Brown-O'Sullivan C, Agarwal S, Akowuah E, et al. PROthrombin complex concentrate versus fresh frozen Plasma for bleeding in adults undergoing HEart SurgerY (PROPHESY-2 trial): a phase III, randomised control trial in England and Wales. Trials. 2026. PMID: 41546086. doi:10.1186/s13063-025-09410-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。